$7.13
-0.14%LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Last Annual Value
511.24M
3-Year CAGR
675%
5-Year CAGR
%
10-Year CAGR
%
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() LENZ Therapeutics, Inc. NASDAQ:LENZ | 511.24M | 487.8% | 359.0% | N/A | |
![]() Savara Inc. NASDAQ:SVRA | 811.10M | 15.0% | 12.8% | 74.4% | |
![]() Rezolute, Inc. NASDAQ:RZLT | 565.90M | 14.5% | 23.8% | 26.8% | |
![]() ARS Pharmaceuticals, Inc. NASDAQ:SPRY | 408.73M | 4.1% | 106.1% | N/A | |
![]() Arbutus Biopharma Corporation NASDAQ:ABUS | 83.32M | 0.8% | 4.9% | 8.6% | |
![]() Geron Corporation NASDAQ:GERN | 2.08B | 4.1% | 8.3% | 6.8% | |
![]() Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | 0.00 | N/A | N/A | N/A | |
![]() Prime Medicine, Inc. NASDAQ:PRME | 0.00 | N/A | N/A | N/A | |
![]() Tyra Biosciences, Inc. NASDAQ:TYRA | 0.00 | N/A | N/A | N/A |
Continue your LENZ research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.